[go: up one dir, main page]

CL2011001829A1 - 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. - Google Patents

3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.

Info

Publication number
CL2011001829A1
CL2011001829A1 CL2011001829A CL2011001829A CL2011001829A1 CL 2011001829 A1 CL2011001829 A1 CL 2011001829A1 CL 2011001829 A CL2011001829 A CL 2011001829A CL 2011001829 A CL2011001829 A CL 2011001829A CL 2011001829 A1 CL2011001829 A1 CL 2011001829A1
Authority
CL
Chile
Prior art keywords
composition
diethylaminoetanoyl
homoerythromycin
desmethyl
aza
Prior art date
Application number
CL2011001829A
Other languages
English (en)
Inventor
Caroline Jane Day
Julien Bruno Filic Darko Kindon Leanda Jane Douillet
Goran Marusic Istuk Zorica Kragol
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41698466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011001829(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CL2011001829A1 publication Critical patent/CL2011001829A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

El compuesto 3'-n-desmetil-4""-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus formas cristalinas; proceso para la preparación de dicho compuesto; composición farmacéutica; y su uso para el tratamiento de enfermedades inflamatorias.
CL2011001829A 2009-01-30 2011-07-28 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo. CL2011001829A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14860909P 2009-01-30 2009-01-30

Publications (1)

Publication Number Publication Date
CL2011001829A1 true CL2011001829A1 (es) 2011-10-14

Family

ID=41698466

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011001829A CL2011001829A1 (es) 2009-01-30 2011-07-28 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.

Country Status (23)

Country Link
US (1) US8227428B2 (es)
EP (1) EP2384333B1 (es)
JP (1) JP5437394B2 (es)
KR (1) KR20110099791A (es)
CN (1) CN102378763A (es)
AR (1) AR075340A1 (es)
AU (1) AU2010209732B2 (es)
BR (1) BRPI1006114A2 (es)
CA (1) CA2748847A1 (es)
CL (1) CL2011001829A1 (es)
CO (1) CO6400226A2 (es)
DO (1) DOP2011000242A (es)
EA (1) EA201101139A1 (es)
ES (1) ES2412059T3 (es)
IL (1) IL213871A0 (es)
MA (1) MA32997B1 (es)
MX (1) MX2011008074A (es)
PE (1) PE20120220A1 (es)
SG (1) SG172782A1 (es)
TW (1) TW201038277A (es)
UY (1) UY32408A (es)
WO (1) WO2010086349A1 (es)
ZA (1) ZA201104653B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101142225B (zh) 2005-01-13 2011-09-07 葛兰素集团有限公司 具有抗炎活性的大环内酯
AU2010209732B2 (en) 2009-01-30 2012-12-20 Glaxo Group Limited Anti-inflammatory macrolide
US20130045939A1 (en) * 2010-03-19 2013-02-21 Catabasis Pharmaceuticals, Inc. Fatty acid macrolide derivatives and their uses
WO2011131749A1 (en) * 2010-04-23 2011-10-27 Glaxo Group Limited New 14 and 15 membered macrolides for the treatment of neutrophil dominated inflammatory diseases
JP6116206B2 (ja) * 2012-11-26 2017-04-19 クリニプロ株式会社 吸入用パウダーの製造方法
JP7100854B2 (ja) * 2017-01-13 2022-07-14 東菱薬品工業株式会社 好中球活性化調節剤
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
TWI847935B (zh) 2020-03-12 2024-07-01 美商碩騰服務公司 氮雜內酯

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US525051A (en) 1894-08-28 Adjustable chair
US3725385A (en) 1970-11-02 1973-04-03 Abbott Lab Process for the demethylation of 3-amino macrolides
EP0126344A2 (en) 1983-05-20 1984-11-28 Abbott Laboratories Tripeptide esters of therapeutic agents
EP0292352A3 (fr) * 1987-05-06 1988-12-28 Adir Et Compagnie Nouveaux dérivés macrolides, leur procédé de préparation et les compositions pharmaceutiques les contenant
SI9011409A (en) 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
EP0895999A1 (en) 1997-08-06 1999-02-10 Pfizer Products Inc. C-4" substituted macrolide antibiotics
HRP980189B1 (en) 1998-04-06 2004-04-30 Pliva Pharm & Chem Works Novel 15-membered lactams ketolides
KR100474229B1 (ko) * 1999-05-18 2005-03-08 화이자 프로덕츠 인크. 마크롤라이드계 항생제의 신규 결정형
HRP20010301A2 (en) 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
AU2003255851B2 (en) 2002-07-08 2009-07-23 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. New compounds, compositions and methods for treatment of inflammatory diseases and conditions
ITMI20021726A1 (it) 2002-08-01 2004-02-02 Zambon Spa Macrolidi ad attivita' antiinfiammatoria.
GB0310986D0 (en) 2003-05-13 2003-06-18 Glaxo Group Ltd Novel compounds
WO2006077501A2 (en) 2005-01-13 2006-07-27 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Decladinosyl-macrolides with anti-inflammatory activity
CN101142225B (zh) * 2005-01-13 2011-09-07 葛兰素集团有限公司 具有抗炎活性的大环内酯
EP1836212B1 (en) 2005-01-14 2011-09-07 Glaxo Group Limited Macrolide compounds containing biotin and photo-affinity group for macrolide target identification
AU2010209732B2 (en) 2009-01-30 2012-12-20 Glaxo Group Limited Anti-inflammatory macrolide

Also Published As

Publication number Publication date
AU2010209732B2 (en) 2012-12-20
US8227428B2 (en) 2012-07-24
KR20110099791A (ko) 2011-09-08
CA2748847A1 (en) 2010-08-05
EP2384333A1 (en) 2011-11-09
EA201101139A1 (ru) 2012-03-30
SG172782A1 (en) 2011-08-29
PE20120220A1 (es) 2012-04-04
US20100197623A1 (en) 2010-08-05
CO6400226A2 (es) 2012-03-15
JP5437394B2 (ja) 2014-03-12
IL213871A0 (en) 2011-07-31
ZA201104653B (en) 2012-02-29
MA32997B1 (fr) 2012-01-02
WO2010086349A1 (en) 2010-08-05
TW201038277A (en) 2010-11-01
AU2010209732A1 (en) 2011-07-21
AR075340A1 (es) 2011-03-23
DOP2011000242A (es) 2011-09-15
BRPI1006114A2 (pt) 2018-02-06
JP2012516304A (ja) 2012-07-19
EP2384333B1 (en) 2013-04-17
CN102378763A (zh) 2012-03-14
MX2011008074A (es) 2011-08-17
ES2412059T3 (es) 2013-07-10
UY32408A (es) 2010-07-30

Similar Documents

Publication Publication Date Title
CL2011001829A1 (es) 3'-n-desmetil-4''-o-(2-dietilaminoetanoil)-6-o-metil-9a-aza-9a-homoeritromicina a, sus sales y formas cristalinas 1, 2 y 3; proceso de preparacion; uso para tratar enfermedades inflamatorias; composicion farmaceutica; y composicion que ademas comprende otro compuesto activo.
CR20110407A (es) Dicianopiridinas alquilamino-sustituidas y sus profármacos de éster de aminoácido
GT200900230A (es) 4-aril-1,4-dihidro-1,6-naftiridinamidas sustituidas y uso
GT200800242A (es) Derivados biciclicos como inhibidores de cetp
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
CO6290656A2 (es) Derivados heterociclicos de urea y metodos de uso de los mismos -211
ECSP10010582A (es) Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
CR20130023A (es) Pirazolo[1,5-a]pirimidinas para tratamiento antiviral
ECSP11011526A (es) Aril-piridinas como inhibidoras de sintasa de aldosterona
UY31228A1 (es) Ariloxazoles sustituidos y su uso
CO6640246A2 (es) Forma cristalina del inhibidor sglt2 bencilbenceno
DOP2009000287A (es) Oxazolidinonas sustituidas y su uso
UY32502A (es) Agentes antihelmínticos y su utilización
UY31860A (es) Piridinas de tiazolo como inhibidoras de la adn girasa
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
UY31922A (es) Compuestos
GT200500360A (es) Compuestos organicos
UY32052A (es) 5-aminopirazoles sustituidos y uso de los mismos
CR20160465A (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil] benzamida (ms-275)
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
UY31133A1 (es) "oxazolidinonas sustituidas y su uso"
UY31864A (es) Derivados de urea hetericíclica y métodos de uso de los mismos-332